PainChek Ltd traded at 0.25 this Tuesday February 3rd, decreasing 0.01 or 3.85 percent since the previous trading session. Looking back, over the last four weeks, PainChek lost 15.25 percent. Over the last 12 months, its price fell by 3.85 percent. Looking ahead, we forecast PainChek Ltd to be priced at 0.25 by the end of this quarter and at 0.23 in one year, according to Trading Economics global macro models projections and analysts expectations.
PainChek Ltd is an Australia-based company, which develops pain assessment technologies. The Company''s principal activities are development and commercialization of mobile medical device applications that provide pain assessment for individuals that are unable to communicate with their carers. The Company''s PainChek Universal is a complete point-of-care solution that combines the existing PainChek Application with the numerical rating scale (NRS). PainChek Application uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalize pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the NRS, a standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.